Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes
Details
Publication Year 2024-02,Volume 99,Issue #2,Page E32-E36
Journal Title
American Journal of Hematology
Publication Type
Research article
Abstract
The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised International Prognostic System Score (IPSS-R) high- or very high-risk myelodysplastic syndromes (HR/vHR-MDS) or chronic myelomonocytic leukemia (CMML). Sabatolimab + HMA had a safety profile similar to that reported for HMA alone and demonstrated durable clinical responses in patients with HR/vHR-MDS. These results support the ongoing evaluation of sabatolimab-based combination therapy in MDS, CMML, and acute myeloid leukemia.
Publisher
Wiley
Keywords
Humans; Azacitidine/therapeutic use; Decitabine/therapeutic use; Antimetabolites, Antineoplastic/therapeutic use; *Myelodysplastic Syndromes/drug therapy; Hepatitis A Virus Cellular Receptor 2/therapeutic use; *Leukemia, Myelomonocytic, Chronic/drug therapy; *Leukemia, Myeloid, Acute/drug therapy; Antibodies/therapeutic use; Treatment Outcome; *Antibodies, Monoclonal
Department(s)
Clinical Haematology
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-01-30 06:27:04
Last Modified: 2024-01-30 06:27:34

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙